Adult Acute Lymphoblastic Leukemia (Adult ALL)
A special issue of Lymphatics (ISSN 2813-3307).
Deadline for manuscript submissions: 31 May 2025 | Viewed by 12
Special Issue Editor
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; measurable residual disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue of the Lymphatics journal aims to enable the rapid publication of contributions and discoveries concerning all aspects of research regarding adult acute lymphoblastic leukemia (ALL), ranging from basic research to clinical applications.
The outcomes of ALL in the adult population have improved substantially over the past decade, driven largely by the development of novel therapies, including immunotherapies (e.g., blinatumomab, inotuzumab ozogamicin and CAR T-cell therapy) and targeted therapies (e.g., potential BCR::ABL1 tyrosine kinase inhibitors). The better risk stratification of patients using cytogenetics and comprehensive molecular testing, as well as high-sensitivity measurable residual disease (MRD) assays, has also contributed to these improvements. However, many patients still unfortunately relapse after standard therapies. To further improve outcomes in adult ALL, new research into the underlying molecular biology of the disease, improved risk stratification models and novel therapeutics are still needed. We are pleased to invite you to share with us your perspectives and research results on adult ALL in this Special Issue. Topics include, but are not limited to, the following:
- Molecular biology and pathology;
- Diagnostic testing;
- Prognostic factors;
- Measurable residual disease (MRD);
- Therapeutics, including chemotherapy, targeted therapies and immunotherapy;
- Novel therapeutic targets;
- Resistance mechanisms to standard therapies;
- Drug toxicities;
- Survivorship.
Dr. Nicholas J. Short
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Lymphatics is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adult acute lymphoblastic leukemia
- adult ALL
- immunotherapies
- targeted therapies
- molecular biology and pathology
- clinical applications
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
